首页 | 本学科首页   官方微博 | 高级检索  
检索        

云南省≥50岁抗病毒治疗失败的HIV/AIDS患者基因型耐药分析
引用本文:刘家法,阮尉月清,孙艾丝,邓雪媚,李健健,杨壁珲,雷素云,张米,董兴齐.云南省≥50岁抗病毒治疗失败的HIV/AIDS患者基因型耐药分析[J].中国热带医学,2020,20(2):121-125.
作者姓名:刘家法  阮尉月清  孙艾丝  邓雪媚  李健健  杨壁珲  雷素云  张米  董兴齐
作者单位:云南省传染病医院,艾滋病关爱中心检验科,云南 昆明 650301
基金项目:“十三五”国家科技重大专项(No.2018ZX10721102-002);云南省医疗卫生单位内设研究机构项目(No.2017NS124);云南省教育厅科学研究项目(No.2018JS252)
摘    要:目的 分析云南省≥50岁艾滋病病毒(HIV)感染者/艾滋病(AIDS)患者(HIV/AIDS患者)抗病毒治疗失败的基因型耐药情况。方法 收集2017年1月1日-2018年12月31日年龄≥50岁且抗病毒治疗时间≥6个月的HIV/AIDS患者检测病毒载量≥1 000 copies/mL的血浆标本,对该样本进行基因型耐药检测。结果 通过基因型耐药检测共获得符合条件pol区序列260条,该人群中耐药发生率为63.1%(164/260)。三类抗病毒药物在使用中,耐药率较高的药物分别是奈韦拉平(NVP)、依非韦伦(EFV)和拉米夫定(3TC),耐药率分别为51.2%(133/260)、50.8%(132/260)、32.3%(84/260),PIs类则较低;耐药率较低的药物分别是替诺福韦(TDF)、齐多夫定(AZT)和克力芝(LPV/r),耐药率分别为11.5%(30/260)、6.2%(16/260)、1.2%(3/260)。耐药突变位点主要有M184、K103、G190和V179,突变率分别为30.8%(80/260)、28.5%(74/260)、14.6%(39/260)和13.1%(34/260)。结论 云南省≥50岁抗病毒治疗失败患者的耐药率相对较高,应加强老年艾滋病患者的管理,对治疗失败的患者,应根据耐药检测结果及时调整抗病毒治疗方案。

关 键 词:人类免疫缺陷病毒1型  抗病毒治疗  基因型耐药  ≥50岁人群  
收稿时间:2019-10-11

HIV/AIDS genotype resistance in patients≥50 years old who failed antiviral therapy in Yunnan
LIU Jiafa,RUAN Weiyueqing,SUN Aisi,DENG Xuemei,LI Jianjian,YANGBihui,LEI Suyun,ZHANG Mi,DONG Xingqi.HIV/AIDS genotype resistance in patients≥50 years old who failed antiviral therapy in Yunnan[J].China Tropical Medicine,2020,20(2):121-125.
Authors:LIU Jiafa  RUAN Weiyueqing  SUN Aisi  DENG Xuemei  LI Jianjian  YANGBihui  LEI Suyun  ZHANG Mi  DONG Xingqi
Institution:Department of Laboratory, Yunnan Provincial Infectious Diseases Hospital/AIDS Care Center, Kunming, Yunnan 650301, China
Abstract:Objective Analysis of genotype resistance of antiviral treatment failure in HIV/AIDS patients aged≥50 years in Yunnan Province. Methods Plasma samples with viral load≥1 000 copies/mL were tested on January 1,2017-December 31, 2018, and aged≥50 with antivirus treatment time≥6 months were tested for genotype resistance. Results A total of 260 qualified pol sequences were obtained by genotype resistance test,and the incidence of drug resistance in this population was 63.1% (164/260).Among the used drugs,the drugs with higher resistance rates were nevirapine (NVP),efavirenz (EFV) and lamivudine (3TC), with drug resistance rates of 51.2% (133/260), 50.8% (132/260) and 32.3% (84/260), respectively. The drugs with lower drug resistance rates were tenofovir (TDF),zidovudine (AZT) and lopinavir/ritonavir (LPV/r), with drug resistance rates of 11.5%(30/260), 6.2% (16/260) and 1.2% (3/260), respectively. Resistance mutation siteswere mainly M184, K103, G190 and V179, with mutation rates of 30.8%(80/260),28.5% (74/260), 14.6%(39/260) and 13.1% (34/260),respectively. Conclusion The drug resistance rate of patients≥50 years old with failed antiviral treatment in Yunnan Province is relatively high,so the management of elderly AIDS patients should be strengthened. For patients who have failed treatment, the antiviral treatment regimen should be adjusted timely according to the results of resistance test.
Keywords:Human immunodeficiency virus type 1  antiviral therapy  genotype resistance  people aged over 50 years  
本文献已被 CNKI 等数据库收录!
点击此处可从《中国热带医学》浏览原始摘要信息
点击此处可从《中国热带医学》下载免费的PDF全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号